Movement Alert｜Natera Intraday Rise 3.03% in Regular Trading, Morgan Stanley Target Increase Reinforces Growth Outlook

Market Focus10-19 23:14

On October 19, Natera rose 3.03% in Regular Trading, trading around $404.09 per share, with turnover of $119 million.

The move was accompanied by renewed market focus on an investment-bank target increase and the company’s recent oncology-testing milestones. Morgan Stanley recently raised its price target to $435 from $355 and maintained an Overweight rating, reinforcing expectations for further valuation re-rating.

Additional background remains supportive: Natera’s multi-cancer early detection assay received FDA Breakthrough Device Designation, Signatera was approved in Japan as a companion diagnostic for muscle-invasive bladder cancer, and skin cancer and breast cancer clinical programs are advancing. Earlier, the company reported second-quarter revenue of $752.8 million, up 37.7% year over year, and lifted full-year revenue guidance to $2.85 billion to $2.91 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment